Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing inorganic arsenic compound and application of pharmaceutical composition

A technology of arsenous acid compound and composition, applied in the preparation of drugs for treating cancer, in the field of pharmaceutical composition containing inorganic arsenic compound and Niclosamide, which can solve the problems affecting the application of anti-cancer and reduce the systemic Toxicity, enhanced inhibitory effect, effect of application safety

Active Publication Date: 2017-09-22
中芝堂药业(山东)有限公司
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the systemic toxicity of arsenic trioxide is a serious problem, which seriously affects the anti-cancer application, so further research is needed to effectively reduce the toxic and side effects of arsenic and improve the anti-cancer efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing inorganic arsenic compound and application of pharmaceutical composition
  • Pharmaceutical composition containing inorganic arsenic compound and application of pharmaceutical composition
  • Pharmaceutical composition containing inorganic arsenic compound and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0013] The lung cancer cells A549 or XWLC-05 cells in the logarithmic growth phase were inoculated in a 96-well plate, and sodium arsenite was dissolved in PBS, with 1000 cells per well. Set CO 2 Samples were added after 24 hours of incubation at 37°C in an incubator. 10 μL PBS solution was added to the control group; 10 μL sodium arsenite solution was added to the sodium arsenite group; 10 μL test substance solution was added to the Niclosamide group; 5 μL test substance solution and 5 μL sodium arsenite solution were added to the combined drug group. The final concentrations of sodium arsenite and Niclosamide are μmol L -1 , each group was set up with 6 multiple wells, and each experiment was repeated 3 times. Put in 37°C CO 2 in the incubator. After 5 days, add 20 μL MTS solution, 37°C CO 2 Continue to incubate in the incubator for 2 hours, and measure the absorbance (A) at 490 nm with an automatic microplate reader. All of the above were completed under the funding o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition containing an inorganic arsenic compound and application of the pharmaceutical composition. The pharmaceutical composition contains the inorganic arsenic compound and Niclosamide and is used for preparing a cancer treatment medicine. Niclosamide has the molecular formula of C13H8Cl2N2O4 and the CAS number of 50-65-7. The pharmaceutical composition has a stronger cancer cell killing function than that of independent use of the inorganic arsenic compound or Niclosamide. The therapeutic dose of the inorganic arsenic compound is reduced, the cancer inhibition effect is enhanced, and the systematic poisonousness of the inorganic arsenic compound is effectively reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing Niclosamide and an inorganic arsenic compound and its application, in particular to a pharmaceutical composition containing an inorganic arsenic compound and Niclosamide and its application in the preparation of medicines for treating cancer. Background technique [0002] In 1971, Han Taiyun of the First Affiliated Hospital of Harbin Medical College transformed traditional Chinese medicine containing arsenic into a drug for treating leukemia. In 1973, Zhang Tingdong, Zhang Peng, etc. applied "Ailing No. 1" to treat chronic myeloid leukemia, which improved the hematological indicators and clinical symptoms of patients. It has been proved that the inorganic compound arsenic trioxide can treat relapsed or refractory acute promyelocytic leukemia (APL), and recent preliminary data show that arsenic trioxide also has an effect on other cancers, so the study of arsenic trioxide as an anticancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/36A61K47/02A61K47/18A61P35/00A61P35/02A61K31/167
CPCA61K31/167A61K33/36A61K47/02A61K47/18A61K2300/00
Inventor 何越峰吴锡南尚莉平妮娜张若冰
Owner 中芝堂药业(山东)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com